Vision Research & Clinical Studies
Valley Retina Institute
Advancing the Future of Eye Care
At Valley Retina Institute, we are dedicated to advancing ophthalmic care through clinical research and innovation. Our research team participates in studies evaluating new treatments, technologies, and approaches to eye care, helping improve outcomes for patients today and in the future.
Working closely with physicians, study sponsors, and participants, our experienced research staff ensures every study is conducted with a strong focus on safety, accuracy, and patient care. Through ongoing research efforts, we help bring promising new advancements in vision care to the communities we serve.
Interested in Participating?
Contact Valley Retina Institute to learn more about current clinical research opportunities and whether a study may be right for you.
LIST OF TRIALS ACTIVELY RECRUITING
EYC-0305
NCT07587515
Open-Label, Multiple Ascending Dose Phase 1b/2a Study of the Safety and Tolerability of Intravitreal (IVT) EYC-0305 in Patients With Neovascular Age-Related Macular Degeneration
Aquarius
NCT07482176
A Multi-center, Randomized, Double-masked, Active-comparator-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
EYETAC
NCT07285070
A Phase 2, Randomized, Double-Masked, Controlled, Proof-of-Concept Study to Evaluate the Safety and Biological Activity of a Water-free Tacrolimus Ophthalmic Solution (NOV05) for the Treatment of Non-Infectious Anterior Uveitis
Astellas
NCT06779773
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY™) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration
SIENNA
NCT06541704
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
ADX-038-202
NCT06990269
A Phase 2, Randomized, Masked, Placebo-Controlled Study of Subcutaneously Administered ADX-038 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Gallop
NCT07215390
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneration
